Survival Outcomes, Recurrence Patterns, and Its Corresponding Therapeutic Management after Conversion Therapy Followed by Curative Resection for Hepatocellular Carcinoma: A Real-World Study.

Furthermore, the median RFS was 16.8 months (95% CI, 13.4–43.0) in the adjuvant therapy group and 15.1 months (95% CI, 10.3–32.4) in the active surveillance group, which also did not reach statistical significance ( p = 0.82, Fig. 4 d).

also in 111,027 other papers